Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Susan P Bell, Douglas W Adkisson, Mark A Lawson...
https://pubmed.ncbi.nlm.nih.gov/25164945/Actively Recruiting
Led by Brigham and Women's Hospital · Updated on 2026-04-06
75
Participants Needed
1
Research Sites
39 weeks
Total Duration
Researchers are evaluating how two different treatments affect heart function in adults with high blood pressure hypertension and thickened heart muscle left ventricular hypertrophy or LVH. This study compares a mineralocorticoid receptor MR antagonist called eplerenone with a thiazide-like diuretic called chlorthalidone. The goal is to see which treatment better improves the small blood vessel function in the heart and the hearts efficiency, potentially leading to improvements in heart structure and function. Participants with hypertension and LVH, who are currently taking ACE inhibitors or angiotensin receptor blockers, will switch to enalapril and stop other blood pressure medicines before starting the study treatments. After a pre-treatment assessment, they will be randomly assigned to receive either eplerenone or chlorthalidone with potassium supplements. The doses will increase after two weeks, and amlodipine may be added later if needed to reach a target blood pressure under 13585 mmHg. Treatment will last for 9 months. During the study, participants will undergo cardiac PET scans to measure coronary microvascular function and cardiac efficiency. Echocardiograms will assess heart function and structure changes. Other tests will measure heart oxygen use, markers of heart injury, and hormone system activity. The main outcomes focus on changes in myocardial flow reserve and myocardial external efficiency after 9 months. Safety and effectiveness will be monitored throughout the study period, which runs until the end of 2027.
CONDITIONS
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
G
Gail K Adler, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Brigham and Women's Hospital
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Eplerenone | Chlorthalidone plus Potassium |
|---|---|---|
| What it is | Eplerenone is a mineralocorticoid receptor antagonist prescribed to lower blood pressure and reduce cardiac strain by blocking the effects of aldosterone. | Chlorthalidone is a thiazide-like diuretic combined with potassium supplementation to treat hypertension. It works by helping the body remove excess sodium and fluid, thereby lowering blood pressure. |
| Role in the trial | Participants are randomized to receive eplerenone to assess its impact on coronary microvascular function and cardiac efficiency. | Participants in this trial arm receive chlorthalidone plus potassium to compare its cardiovascular and vascular effects against eplerenone. |
| Primary use | Eplerenone is used to manage high blood pressure and prevent heart muscle enlargement or damage, especially in individuals with hypertrophy. | Chlorthalidone lowers blood pressure and reduces cardiovascular complications. It is considered a standard and effective choice for treating hypertension. |
| How it is given | Eplerenone is started orally at 50 mg and increased to 100 mg after 2 weeks, taken daily. | Chlorthalidone 12.5 mg plus potassium 10 mEq is started daily and increased after 2 weeks to 25 mg chlorthalidone and 20 mEq potassium, taken daily. |
| Evidence status | Evidence supports eplerenone’s capacity to reduce left ventricular hypertrophy and improve cardiac efficiency in hypertension. | Strong, high-quality evidence demonstrates chlorthalidone's efficacy in lowering blood pressure and reducing cardiovascular risk in diverse populations with hypertension. |
| Important limitations | Long-term clinical event data in this specific population are limited. Information on head-to-head comparison with thiazide diuretics for microvascular outcomes is still emerging. | Despite strong evidence for reducing blood pressure, long-term effects on cardiac efficiency and myocardial oxygen use in this genetic and imaging-defined population are less studied. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration not specified
Participants are transitioned to enalapril 10 mg and weaned off their other anti-hypertensive medications before the pre-treatment assessment.
Visit(s) for medication adjustment and monitoring
Duration - 9 months
Participants are randomized to receive either eplerenone or chlorthalidone plus potassium. Doses are increased at 2 weeks, and amlodipine may be added at 6 weeks or later if needed to control blood pressure.
Baseline visit and follow-up visits during treatment as needed
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Susan P Bell, Douglas W Adkisson, Mark A Lawson...
https://pubmed.ncbi.nlm.nih.gov/25164945/George L Bakris, Rajiv Agarwal, Stefan D Anker...
https://pubmed.ncbi.nlm.nih.gov/33264825/Wunan Zhou, Jenifer M Brown, Navkaranbir S Bajaj...
https://pubmed.ncbi.nlm.nih.gov/32221588/H Laine, C Katoh, M Luotolahti...
https://pubmed.ncbi.nlm.nih.gov/10595955/Iris Z Jaffe, Michael E Mendelsohn
https://pubmed.ncbi.nlm.nih.gov/15718497/Rene Baudrand, Luminita H Pojoga, Anand Vaidya...
https://pubmed.ncbi.nlm.nih.gov/26432671/Ole-Jakob How, Ellen Aasum, David L Severson...
https://pubmed.ncbi.nlm.nih.gov/16443782/Guillaume Galmiche, Anne Pizard, Alexandre Gueret...
https://pubmed.ncbi.nlm.nih.gov/24296280/Eveline M Oestreicher, Diego Martinez-Vasquez, James R Stone...
https://pubmed.ncbi.nlm.nih.gov/14581407/Linda R Peterson, Pilar Herrero, Kenneth B Schechtman...
https://pubmed.ncbi.nlm.nih.gov/15123530/Brigham and Women's Hospital
Lead Sponsor